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Objective: This study examined the risk of accidental events in older adults prescribed a sedating 
antidepressant, long-acting benzodiazepine, short-acting benzodiazepine, and nonbenzodiaz-
epine, relative to a reference group (selective melatonin receptor agonist).
Methods: This was a retrospective cohort analysis of older adults ($65 years) with newly initi-
ated pharmacological treatment of insomnia. Data were collected from the Thomson MarketScan® 
Medicare Supplemental and Coordination of Benefits databases (January 1, 2000, through June 
30, 2006). Probit models were used to evaluate the probability of an accidental event.
Results: Data were analyzed for 445,329 patients. Patients taking a long-acting benzodiazepine 
(1.21 odds ratio [OR]), short-acting benzodiazepine (1.16 OR), or nonbenzodiazepine (1.12 
OR) had a significantly higher probability of   experiencing an   accidental event during the first 
month following treatment initiation compared with patients taking the reference medication 
(P , 0.05 for all). A significantly higher probability of   experiencing an accidental event was 
also observed during the 3-month period following the initiation of treatment (1.62 long-acting 
benzodiazepine, 1.60 short-acting benzodiazepine, 1.48 nonbenzodiazepine, and 1.56 sedating 
antidepressant; P , 0.05).
Conclusions: Older adults taking an SAD or any of the benzodiazepine receptor agonists appear 
to have a greater risk of an accidental event compared with a reference group taking an MR.
Keywords: insomnia, accidental events, benzodiazepine receptor agonist, melatonin receptor 
agonist, older adults
Introduction
Insomnia is characterized by inadequate or poor-quality sleep because of difficulty 
falling asleep (sleep-onset insomnia), difficulty staying asleep (sleep maintenance 
insomnia), or early morning awakening, and is classified as transient or chronic 
(Diagnostic and Statistical Manual of Mental Disorders, edition IV, Text Revision). 
Transient insomnia is common and generally occurs as a result of anxiety, stress, 
environmental factors (ie, noise, extreme temperatures, change in the surrounding 
environment), sleep–wake schedule alterations, and medication-related side effects.1 
Chronic insomnia affects approximately 10% of the adult population in the US and 
is more complex, often associated with a combination of comorbid factors, including 
medical, psychiatric, and sleep disorders.2,3
Both types of insomnia are common in older adults, and the prevalence increases 
with advancing age.3–5 Because of changes in sleep architecture, older adults are more 
likely than younger adults to experience increased nocturnal awakenings, interrupted 
sleep, and decreased sleep efficiency.6 A study by the National Institute of Aging Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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of noninstitutionalized older adults indicated that 28% of 
respondents had difficulty falling asleep, whereas another 
42% of respondents reported having difficulty falling asleep 
and staying asleep.7
The treatment of insomnia includes both behavioral (eg, 
cognitive behavioral therapy) and   pharmacological   therapies 
(sedating antidepressants, long-acting and   short-acting 
  benzodiazepines, nonbenzodiazepine   hypnotics, and a selec-
tive melatonin receptor agonist). Although   benzodiazepines 
effectively promote sleep, they have a relatively long 
  duration of action, which can be problematic, as the thera-
peutic action of these medications can extend into the 
waking hours and cause daytime sedation.8 Use of these 
medications is   associated with an increased risk of adverse 
events such as physical disability, falls, and motor vehicle 
accidents in older adults.9 Studies suggest that older adults 
who are prescribed a benzodiazepine (either long-acting or 
short-acting) have an increased risk of falling at least once 
within 90 days of initiating treatment and are at greater risk 
for motor vehicle accidents.10,11 Nonbenzodiazepine hypnot-
ics are used specifically for the management of insomnia 
and were developed to reduce the potential for side effects 
associated with the benzodiazepine medications.12 Although 
each of the nonbenzodiazepine hypnotic medications has 
a different   pharmacokinetic profile, research suggests 
that falls, fractures, and motor vehicle accidents are also 
a concern with these medications, with serious economic 
consequences.13–15 Off-label use of sedating antidepressants, 
particularly trazodone, is also common in the treatment of 
insomnia. Although studies have supported the efficacy of 
trazodone in improving sleep in patients with both primary 
and comorbid insomnia, trazodone can produce sedation, 
orthostatic hypotension, and blurred vision, all of which 
increase the risk of falls.16 Recent studies suggest that the 
newest class of insomnia medications, the selective melatonin 
receptor agonist, has a sleep-promoting action that does not 
appear to cause   balance impairments, rebound insomnia, or 
next-day cognitive or psychomotor effects that may lead to 
increased accident risks in older adults.17–20
The increased risk of accidental events associated with 
the use of insomnia medications is particularly troublesome 
in older adults because they are much more likely to suffer 
injuries from falls, fractures, and motor vehicle accidents.21–23 
The use of insomnia medications may compound this risk. 
However, the assessment of risk is complex and may be 
confounded by factors associated with untreated insomnia, 
which by itself has been shown to increase the risks of an 
accidental event.24,25 The goal of the current study was to 
examine the risk of accidental events in a population of older 
adults ($65 years of age) prescribed common insomnia 
medications.
Patients and methods
Study design
A retrospective cohort analysis comparing the risk of 
accidental events in patients prescribed common   insomnia 
medications was conducted based on the Thomson   Medstat 
MarketScan® 2000-Q2 2006 Medicare Supplemental and 
Coordination of Benefits databases. These data (  representing 
both the employer-paid and Medicare-paid components 
of care) include the health insurance claims across the 
  continuum of care (inpatient, outpatient, outpatient   pharmacy, 
and enrollment data) for retirees covered by their previous 
employer through privately insured fee-for-service, point-of-
service, or capitated health plans. This information comes 
from administration claims and there is no independent 
validation of the data using medical charts. However, claim 
entries are fully adjudicated by the payer, and any data that 
appear to be erroneous (ie, claims with costs that exceed 
reasonable limits) are excluded on an individual basis. Cost 
thresholds for exclusion of claims are in line with what 
other administration claims databases use, including those 
used by the Healthcare Cost and Utilization Project, which 
is developed by the Agency for Healthcare Research and 
Quality using hospital claims data. Depending on the year, 
the Medicare supplemental databases include between 2.5 
and 3.1 million individuals, and these data are projectable 
to the US population with Medicare supplemental insurance 
(12.7 million retirees).
Study population
Older adults ($65 years) with at least one outpatient phar-
maceutical claim for an identified insomnia   medication 
(long-acting benzodiazepine [lorazepam, quazepam, and 
flurazepam], short-acting benzodiazepine [estazolam, 
temazepam, and triazolam], nonbenzodiazepine hypnotic 
[zolpidem, zaleplon, and eszopiclone], sedating antidepres-
sant [trazodone], and selective melatonin receptor agonist 
[ramelteon]) were included in the analysis. A 12-hour 
  half-life was used as the cutoff between long-acting and 
short-acting benzodiazepines. Because some of these medi-
cations, specifically lorazepam and trazodone, may have 
multiple indications, only patients with specific doses (2 mg 
or less for lorazepam; 100 mg or less for trazodone) or those 
  taking a certain number of pills supplied per month (no more 
than 30 pills per month) were selected for study inclusion. Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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Patients with injectible formulations of lorazepam were also 
excluded from the study.
Because insomnia often is not coded on a patient’s medi-
cal claim, an insomnia diagnosis was not required for study 
inclusion. If an insomnia diagnosis was present prior to the 
insomnia medication claim, it was included as a study cova-
riate. The study population was further restricted to those 
patients who were considered new initiators of   insomnia 
medication therapy (ie, no evidence of a prescription 
  insomnia medication during the 3-month period prior to study 
initiation) and who had at least 9 months of health insurance 
eligibility data (6 months prior to the identification of the 
first insomnia medication claim and 3 months following the 
first insomnia medication claim). Patients with evidence of 
nursing home admissions (n = 2526; 0.5% of population), 
those with insomnia medication polytherapy (n = 10,672; 
2.0% of population) during the study period, and Medicare 
beneficiaries ,65 years of age (n = 62,571, 12.0% of the 
population) were excluded from the analysis.
Measurements
Clinical characteristics in this analysis were measured using 
the Charlson Comorbidity Index (Deyo adaptation) and the 
International Classification of Diseases – 9th edition (ICD-
9-CM) codes from the patients’ medical claims data for the 
6-month period preceding the initiation of treatment with 
insomnia medication. Several factors that may contribute to 
accident risks were assessed because they are meaningful to 
patients and to the healthcare system. Comorbid disorders 
that may have affected accident risk were recorded during the 
study period. These comorbidities included adjustment and 
stress disorders, alcohol and drug disorders, schizophrenia 
and other psychotic disorders, seizure disorders, abnormal 
movements and Parkinsonism disorders, mood disorders, pain 
disorders, and other mental health disorders. Concomitant 
medications that may also have affected accident risk were 
recorded based on the presence of at least one outpatient 
pharmaceutical claim during the study period. These included 
anticholinergic/antiparkinsonian/antispastic agents, opiate 
antagonists, analgesics, antidiabetic agents, antimanic agents, 
anxiolytics, antidepressants, benzodiazepines, and anticon-
vulsants (the concomitant antidepressants, benzodiazepines, 
and anticonvulsant medication groups did not include those 
used to qualify patients for study inclusion).
The incidence of accidental events was evaluated for 
two time periods: accidental events occurring during the first 
30 days of insomnia therapy and events occurring during 
the first 3 months of insomnia therapy. Accidental events 
(falls, fractures, dislocations, sprains/strains, open wounds, 
intracranial injuries, injuries caused by cutting/piercing 
instruments, accidents caused by machinery, electrocution, 
and motor vehicle accidents) were chosen to represent the 
variety of impairments that may affect daily routines and 
were identified using External Causes of Injury Codes (based 
on the International Classification of Diseases) and routine 
ICD-9-CM codes in the claims files.
Statistics
Chi-square tests were used for categorical variables, and 
two-sided t tests were used for continuous variables. The 
descriptive analysis was performed using SAS (SAS Institute 
Inc., Cary, NC, USA) version 9.1. The modeled estimations 
of the probability of accidental events and time to accidental 
events were performed with Stata (  StataCorp, College Sta-
tion, TX, USA) version 9. To compute the regression-adjusted 
probability of an accidental event for the two defined time 
periods, multivariate analyses were   conducted using probit 
models with variable inclusion based on a priori hypotheses. 
The a priori hypotheses were: 1) patients prescribed a selec-
tive melatonin receptor agonist would have a lower risk of 
an accidental event during the period   immediately following 
the initiation of therapy, and 2) given the presence of an acci-
dental event, the time to such an event would be longer for 
patients prescribed a selective melatonin receptor agonist.
Probit regression models extend the principles of gener-
alized linear models to better treat the case of dichotomous 
and categorical variables – in this case, the probability of an 
accidental event (0 if no event and 1 if evidence of an event). 
Probit is a variant of logit modeling but is based on different 
data assumptions; specifically, logit analysis is based on log 
odds, whereas probit uses the cumulative normal probability 
distribution. These multivariate models included the follow-
ing covariates: gender, age, Charlson Comorbidity Index, 
presence of select comorbidities, presence of an insomnia 
diagnosis, and presence of concomitant medications of 
interest. Because no accidental events occurred during either 
the first 30 days or 3 months of insomnia therapy for patients 
prescribed the reference drug cohort (a selective melatonin 
receptor agonist), model convergence was not achieved. The 
existence, finiteness, and uniqueness of maximum likeli-
hood estimates for the probit regression model depend on 
the pattern of data points in the observation space. If the 
data are completely or partially separated, it may not be 
possible to obtain reliable maximum likelihood estimates 
because convergence may not occur. Model nonconvergence 
occurs because one or more parameters in the model become Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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  theoretically infinite – typically because either the model 
perfectly predicts the response or there are more parameters in 
the model than can be estimated because the data are sparse. 
In this particular analysis, model nonconvergence was a direct 
result of zero observations for the dependent variable of 
interest for the reference group for the drug cohort   variable. 
In an effort to evaluate the probability of an accidental event 
within a multivariate framework, a random patient within the 
selective melatonin receptor agonist cohort was assigned a 
nonzero value for the dependent variable (presence of an acci-
dental event variable).26 This was done in an iterative manner 
by randomly selecting a patient in the selective melatonin 
receptor agonist group and assigning them a “1” value for the 
presence of an accidental event. We completed this process 
numerous times, each time selecting another random patient 
to be assigned the “1” value for the   presence of an   accidental 
event and re-running the probit model. Model statistics, coef-
ficients (magnitude and direction) and P values resulted in the 
same conclusions each time. This data manipulation enabled 
convergence of the probit regression models and produced 
interpretable coefficients.
Results
Demographics
The sample used to estimate the probability of an accidental 
event consisted of 445,329 Medicare patients. A flow-chart 
describing the derivation of this sample is shown is   Figure 1. 
Demographic and clinical characteristics are shown in Table 1. 
The majority of patients were prescribed   long-acting benzodiaz-
epines and nonbenzodiazepine hypnotics (36.38% and 35.25%, 
respectively). The remaining patients were prescribed short-
acting benzodiazepines (18.21%), a sedating antidepressant 
(9.94%), or a selective melatonin receptor agonist (0.22%).
Patients in each cohort except the reference cohort (mela-
tonin receptor agonist) experienced at least one accidental event 
during the first 30 days of insomnia treatment, and the number 
of accidental events after 90 days was increased for all cohorts 
except the melatonin receptor agonist cohort (Table 2). Because 
With 6 months of continuous eligibility prior to
medication claim 
n = 844,089 
With 3 months of continuous eligibility following 
medication claim 
n = 533,600 
With no evidence of insomnia medication 
polytherapy 
n = 520,402 
Aged 65 years or older 
n = 457,831 
Excluding those with no age information 
n = 445,329 
With no evidence of nursing home admission 
n = 531,074 
Final sample 
n = 445,329 
Total number of medicare patients with at least one 
new claim for an included insomnia medication 
n = 1,101,997 
Figure 1 Flow-chart of the derivation of the sample population.Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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patients in the reference cohort experienced no accidental events, 
the time interval to an event was right censored at 30 days for 
the first follow-up period and 90 days for the full study.
Probability of an accidental event
Table 3 shows the results of the probit regressions of the 
risk of an accidental event during the 30-day and 3-month 
periods following the initiation of insomnia drug therapy. The 
probability of an accidental event was significantly greater 
(P , 0.05) at all time points for patients taking a long-acting 
benzodiazepine, a short-acting benzodiazepine, or a nonben-
zodiazepine hypnotic when evaluated against the risk for 
patients in the reference cohort. Patients   taking a   sedating 
antidepressant demonstrated a significantly increased prob-
ability of an accidental event only during the 3-month 
time period. At the end of the study (3 months), risks of an 
  accidental event were 1.48 to 1.62 times greater for patients 
in all evaluated medication cohorts compared with those in 
the reference cohort. Additional variables that affected the 
probability of an accidental event are shown in Table 3.
Discussion
In this study of commonly prescribed hypnotic medications, 
patients who were prescribed a benzodiazepine, nonbenzodi-
azepine hypnotic, or sedating antidepressant had   significantly 
higher risks of an accidental event during the 30-day and 
3-month periods following pharmacotherapy initiation 
compared with the reference cohort of a melatonin receptor 
agonist that had no observed accidental events. Nonbenzodi-
azepine hypnotics were developed to reduce the potential for 
side effects associated with the benzodiazepine medications. 
However, this analysis suggests that the risk of an accidental 
event is similar among all of the sedating hypnotics.
The trade-off between improved sleep with hypnotic agents 
and the potential risk of accidents and falls is an ongoing issue 
for health professionals who treat insomnia in older adults as 
Table 1 Demographic and clinical characteristics of the study population
Patient  
characteristic
Long-acting  
benzodiazepine  
n = 162,015
Short-acting  
benzodiazepine  
n = 81,083
Nonbenzodiazepine  
n = 156,987
Sedating  
antidepressant  
n = 44,256
Melatonin  
receptor agonist   
n = 988
Male, n (%) 52,408 (32.35) 32,883 (40.55) 62,547 (39.84) 14,685 (33.18) 373 (37.75)
Female, n (%) 109,607 (67.65) 48,200 (59.45) 94,440 (60.16) 29,571 (66.82) 615 (62.25)
Age, mean (SD) 75.96 (7.28) 76.34 (7.17) 75.09 (6.96) 75.63 (7.34) 75.39 (7.19)
noncapitated insurance plan, n (%) 41,418 (25.56) 32,558 (40.15) 15,510 (9.88) 13,047 (29.48) 36 (3.64)
capitated insurance plan, n (%) 120,597 (74.44) 48,525 (59.85) 141,477 (90.12) 31,209 (70.52) 952 (96.36)
insomnia diagnosis, n (%) 527 (0.33) 756 (0.93) 2,058 (1.31) 606 (1.37) 77 (7.79)
charlson comorbidity index,  
mean (SD)
1.10 (2.01) 1.04 (1.89) 1.21 (2.02) 0.86 (1.66) 1.22 (1.80)
comorbiditiy, n (%) 27,588 (17.03) 9,530 (11.75) 22,507 (14.34) 9,102 (20.57) 244 (24.70)
  Adjustment disorder and stress 663 (0.41) 228 (0.28) 417 (0.27) 250 (0.56) 3 (0.30)
  Psychotic disorder 2,261 (1.40) 612 (0.75) 1,379 (0.88) 754 (1.70) 15 (1.52)
  Mood disorder 6,086 (3.76) 2,522 (3.11) 5,527 (3.52) 1,778 (4.02) 32 (3.24)
  Anxiety 2,329 (1.44) 801 (0.99) 2,023 (1.29) 722 (1.63) 29 (2.94)
  Other mental health disorder 5,248 (3.24) 1,987 (2.45) 5,529 (3.52) 1,389 (3.14) 46 (4.66)
  Alcohol or drug abuse 5,314 (3.28) 1,819 (2.24) 4,379 (2.79) 2,733 (6.18) 88 (8.91)
  Seizure disorder 4,185 (2.58) 900 (1.11) 2,206 (1.41) 1,073 (2.42) 37 (3.74)
    Abnormal movement or  
Parkinsonism disorder
5,451 (3.36) 2,211 (2.73) 5,828 (3.71) 1,706 (3.85) 55 (5.57)
  Headache 7,486 (4.62) 1,689 (2.08) 3,520 (2.24) 2,462 (5.56) 41 (4.15)
  Pain 16,623 (10.26) 4,620 (5.70) 10,538 (6.71) 6,025 (13.61) 158 (15.99)
concomitant medication, n (%) 74,805 (46.17) 36,838 (45.43) 84,048 (53.54) 21,811 (49.28) 671 (67.91)
  Antihistamines 12,098 (7.47) 5,316 (6.56) 15,229 (9.70) 3,112 (7.03) 134 (13.56)
    Anticholinergics/ 
antiparkinsonians/antispastics
3,605 (2.23) 1,380 (1.70) 3,169 (2.02) 848 (1.92) 21 (2.13)
  Opiate antagonists 6 (0.00) 2 (0.00) 7 (0.00) 4 (0.01) 0 (0.00 )
  Analgesics 30,237 (18.66) 18,013 (22.22) 38,844 (24.74) 7,915 (17.88) 276 (27.94)
  Antidiabetics 17,428 (10.76) 8,915 (10.99) 20,906 (13.32) 4,809 (10.87) 158 (15.99)
  Antimanic 337 (0.21) 124 (0.15) 290 (0.18) 112 (0.25) 3 (0.30)
  Anxiolytic 3,558 (2.20) 1,462 (1.80) 3,426 (2.18) 1,020 (2.30) 58 (5.87)
  Antidepressants 28,119 (17.36) 10,783 (13.30) 27,125 (17.28) 9,765 (22.06) 318 (32.19)
  Benzodiazepines 9,161 (5.65) 5,857 (7.22) 13,904 (8.86) 3,659 (8.27) 129 (13.06)
  Anticonvulsants 9,801 (6.05) 4,026 (4.97) 10,357 (6.60) 3,398 (7.68) 155 (15.69)
Abbreviation: SD, standard deviation.Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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Table 2 Accidental events detected during the 3-month follow-up period after initial prescription
Measurement Long-acting  
benzodiazepine  
n = 162,015
Short-acting  
benzodiazepine  
n = 81,083
Nonbenzodiazepine  
n = 156,987
Sedating  
antidepressant  
n = 44,256
Melatonin  
receptor agonist   
n = 988
1-month follow-up
number of patients with at least  
1 accidental event, n (%)
270 (0.17) 114 (0.14) 184 (0.12) 55 (0.12) 0 (0.00)
Mean time to accidental event,  
days (SD)
13.39 (9.75) 12.39 (9.23) 12.65 (9.22) 14.62 (8.99) nA
3-month follow-up
number of patients with at least  
1 accidental event, n (%)
648 (0.40) 302 (0.37) 440 (0.28) 158 (0.36) 0 (0.00)
Mean time to accidental event,  
days (SD)
40.75 (27.39) 42.90 (27.95) 38.81 (26.65) 44.02 (26.46) nA
Abbreviations: nA, not applicable; SD, standard deviation.
Table 3 risk factors associated with an accidental event
Risk factor 1-month follow-up period 3-month follow-up period
Coefficient Odds ratioa Coefficient Odds ratioa
Long-acting benzodiazepine treatmentb 0.1907 1.21* 0.4818 1.62*
Short-acting benzodiazepine treatmentb 0.1524 1.16* 0.4704 1.60*
nonbenzodiazepine treatmentb 0.1098 1.12* 0.3888 1.48*
Sedating antidepressant treatmentb 0.1038 1.11 0.4429 1.56*
Age 0.0225 1.02* 0.0221 1.02*
Female gender −0.0106 0.99 0.0032 1.00
insomnia diagnosis (pre-period) −0.0452 0.96 −0.0243 0.98
charlson comorbidity index score (pre-period) 0.0140 1.01* 0.0131 1.01*
concomitant medication: analgesics 0.1350 1.14* 0.1097 1.12*
concomitant medication: antidepressants 0.1040 1.11* 0.1203 1.13*
concomitant medication: benzodiazepines 0.0737 1.08 0.0338 1.03
concomitant medication: anticonvulsants 0.0622 1.06 0.0762 1.08*
comorbidity: alcohol or drug abuse 0.4089 1.51* 0.2764 1.32*
comorbidity: seizure disorder 0.0661 1.07 0.0849 1.09*
comorbidity: abnormal movement/Parkinsonism 0.1434 1.15 0.1659 1.18*
comorbidity: general mental health disorder 0.2803 1.32* 0.2216 1.25*
Notes: *P , 0.05; aOdds ratios compare the risk of accidental event for the listed variable relative to its specific reference group while controlling for all the other variables 
in the model; brisk of an accidental event for the medication cohorts was compared with the reference cohort (melatonin receptor agonist).
well as regulatory agencies. Previous research often focused on 
nursing home populations or only specific notable events (ie, hip 
fractures). The earliest   evaluations also included agents, such as 
barbiturates, that are no longer the standard of care. However, a 
recent review by Glass et al described some rather compelling 
data associating sedative hypnotics with adverse events in the 
treatment of   insomnia in older adults.11 Using a meta-analysis, 
the authors   demonstrate that although sedatives improve sleep 
quality and amount of sleep, these benefits are outweighed by 
the associated   excessive sleepiness that may put patients at risk 
for falls, injurious behaviors, and motor vehicle accidents.11 
The number needed to treat for improved sleep quality was 
13, whereas the number needed to harm for any adverse event 
was 6.11 A key literature review on the treatment of chronic 
insomnia in geriatric patients determined that long-term use 
of sedative hypnotics for insomnia lacks an evidence base and 
identified concerns for potential adverse drug effects, including 
anterograde amnesia, motor disturbances,   excessive daytime 
sleepiness, and the potential for   accidental events.9 Further 
complicating the issue is a recent large retrospective study in 
Michigan, USA which determined that in elderly nursing-home 
residents, insomnia, but not hypnotic use, is associated with a 
greater risk of subsequent falls.24 However, the current study 
used a different patient population that was substantially larger 
(N = 445,329) and healthier (most patients were free from 
comorbid conditions with no evidence of nursing home admis-
sions).The endpoints in this study were also broader, including 
a variety of   injuries, than previous assessments of accident risk 
that mostly focused on falls and fractures. Overall, the current 
research expands on the results from previous studies and 
increases the understanding of accident risk associated with 
the use of hypnotic agents in older adults.Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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There are several studies of accident rates both in the general 
population and in those with insomnia. For example, accord-
ing to the National Center for Injury Prevention and Control, 
the rate of unintentional nonfatal injuries in the United States 
between 2001 and 2007 was 9305 per 100,000 people (0.093).27 
When the data were restricted to those .65 years, the rate was 
7852.52 per 100,000 people (0.079).27 Accident rates in people 
with untreated insomnia vary between studies but most show an 
increase in   accidents among those with insomnia. In a Japanese 
study, data from 2903 workers between the ages of 16 and 83 
years showed that insomnia symptoms were associated with an 
adjusted odds ratio of 1.3 for the occurrence of   occupational 
  injuries.28 A study by Balter and Uhlenhuth in the US   population 
showed that past-year prevalence rates for serious   accidents/
injuries in subjects with chronic untreated insomnia were 4.5 
times higher than normal controls (9% and 2%,   respectively).25 
These findings are similar to a French study that showed patients 
with severe insomnia were more likely than good sleepers to 
experience work-related accidents over a 12-month time period 
(8% and 1%, respectively).29 In this study, the range of acci-
dent rates for older adults (0.28 to 0.40) was greater than that 
in the general population (0.079), but that may have been due 
to several factors and not simply the presence of insomnia or 
hypnotics. In subjects of all ages with untreated insomnia, the 
rate of accidents is much higher than in normal controls.25,28,29 
It is possible that the accident rates in this study, although 
higher than those in the overall population, may actually have 
been reduced compared with the potential accident rates if the 
patients had not been treated for insomnia.
Several limitations of the data and these analyses should be 
noted. First, the presence of insomnia was identified by prescrip-
tion records only.  Although the prescription hypnotic medica-
tions captured in this study are consistent with those of other 
published studies, it is not possible to confirm that these medica-
tions were indeed used for insomnia treatment. We attempted 
to mitigate this possibility by eliminating doses that may be 
used for other conditions (ie, trazodone at doses .100 mg for 
depression treatment). Second, there was no control group of 
untreated insomniacs, which may have affected the analysis due 
to the risk of accidental events associated with insomnia itself. 
It is possible that, in this study, all of the hypnotics reduced 
the overall accident rate associated with untreated insomnia. 
An overview of the accident rates in the population with and 
without insomnia has been provided as a comparison with the 
rates found in this study. Third, the results of this study should 
be viewed in light of limitations that are inherent in retrospec-
tive claims data analysis. Correct categorization of insurance 
database information depends on correct coding by clinicians 
and other medical staff. The accuracy of diagnostic coding 
cannot be evaluated in a claims-based study. Patients may also 
receive treatment that is not submitted to their health plan for 
reimbursement and thus not included in claims data. Also, 
consideration of the methodology used to ensure that model 
convergence was achieved should be taken into account when 
evaluating the risk of accidental events. Finally, this analysis 
included claims data from 2000 through the second quarter of 
2006, but ramelteon was not approved until 2005, which limits 
the number of patients and the amount of data available for 
comparison with the other medication classes. It is possible that 
there may have been a time trend bias in the analysis. However, 
this would occur only if the risks for an accidental event had 
changed over the years for the other medications included in 
the analysis. Also, if accidental events were more differentially 
reported prior to 2005, the risk assessments may have been 
altered, but this seems unlikely.
The small number of patients taking a melatonin receptor 
agonist (compared with the other drug cohorts) does make it dif-
ficult to draw definitive conclusions from this study. The small 
sample size may have contributed to the lack of an accidental 
event in the melatonin receptor agonist cohort. However, model 
convergence was used to adjust for the lack of an event, and the 
small sample size was accounted for in the statistical analyses. 
For these reasons, the melatonin receptor agonist cohort was 
used as a reference for comparison with the other medication 
cohorts, and no specific conclusions were drawn relating to the 
melatonin receptor agonist (or between any of the cohorts). In 
the future, additional studies with a greater number of subjects 
receiving melatonin receptor   agonists may be needed to deter-
mine how to most appropriately use hypnotics in older adults, 
both to treat insomnia successfully and to reduce the risks of 
accidental events.
Although more work is warranted to evaluate whether these 
findings can be supported in other patient populations, these 
results are nevertheless important. Results of this study add to 
the literature on the risk of accidental events in patients who 
are taking insomnia medications. Finally, although the sample 
size was small, the data in this retrospective claims analysis 
support findings from double-blind, placebo-controlled 
studies that indicate that selective melatonin receptor agonists 
lack the apparent drug-related or residual effects that can lead to 
accidental events, making the case for more selectively targeted 
treatments for insomnia.17,19,30,31
Conclusions
Older adults taking a sedating antidepressant or any of the 
benzodiazepine receptor agonists appear to have a greater Drug, Healthcare and Patient Safety
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risk of an accidental event compared with a reference group 
taking a selective melatonin receptor agonist.
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